From: Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report
Ipi → Ipi
Ipi + Nivo→Nivo
Robert et al. [5] (n = 38)
Chiarion-Sileni et al [7] (n = 51)
Lebbe et al [10] (n = 122)
Pollack et al [8] (n = 80)
ORR (%)
18.4
11.8
23.0
70.0
DCR (%)
60.5
54.9
48.4
88.8
All grade irAE (%)
57.9
21.6
64.0
50.0
Grade 3/4 irAE (%)
10.5
13.5
30.0